This book presents a comprehensive overview of intricate mechanisms of virulence, antimicrobial resistance, immune evasion, and biofilm formation of Staphylococcus aureus. It provides insights into mechanisms by which S. aureus acquires and sustains drug resistance, including gene mutation, efflux pumps, and horizontal gene transfer. The book examines the latest advancements in pathogen detection, application of artificial intelligence, and systems biology approaches in S. aureus research. In turn, the book examines host immune responses to persistent S. aureus infections, focusing on immune modulation, chronic inflammation, and evasion mechanisms. Further, the chapters review novel therapeutic interventions, including quorum sensing inhibitors, plant-derived antimicrobials, and innovative vaccine development. By integrating genomic research, computational biology, and emerging drug discovery techniques, this book outlines the next generation of treatment options for S. aureus-related infections.
Key Features:
· Explores the molecular and genetic mechanisms underlying S. aureus virulence, drug resistance, and host adaptation
· Examines antimicrobial resistance mechanisms and the growing challenge of multidrug-resistant S. aureus strains
· Discusses the role of biofilm formation and quorum sensing in disease persistence and treatment resistance
· Presents state-of-the-art diagnostic technologies, including AI-driven detection and molecular profiling techniques
· Reviews novel therapeutic approaches, including plant-based antimicrobials, quorum sensing inhibitors, and development of vaccines
This book is an important resource for students and researchers of microbiology and pharmaceutical sciences.
Table of Contents:
Section I: Pathogenesis and Molecular Foundations of Staphylococcus aureus. 1. Introduction to Staphylococcus aureus: General Overview. 2. Unraveling the pathogenesis of Staphylococcus aureus. 3. Understanding Drug Resistance Mechanisms in Staphylococcus Aureus. 4. Antimicrobial Resistance Trends in Staphylococcus aureus. 5. Genetic and Molecular Insights into Staphylococcus aureus Pathogenesis and Therapeutic Potential of Bioactive Compounds. Section II: Host-Pathogen Interactions and Immune Evasion Mechanisms. 6. Investigating Host Immune Response to Chronic Staphylococcus aureus Infection. 7. Navigating Staphylococcus aureus Mastitis: Detection, Management and Prevention. 8. Chronic Staphylococcus Infections and Cancer: Mechanisms and Treatments. Section III: Biofilm Formation and Quorum Sensing. 9. Exploring Quorum Sensing and Biofilm Formation in Staphylococcus aureus. 10. Current Techniques for Detecting Biofilm Formation. 11. Harnessing Quorum Sensing Inhibitors for Biofilm Control in Staphylococcus aureus. Section IV: Innovative Therapeutic Strategies and Future Research Directions. 12. Advanced Approaches to Identify, Characterize, and Track the Spread of Staphylococcus aureus. 13. AI Applications in Detecting, Treating and Research of Staphylococcus Aureus. 14. Applications of Systems Biology Tools to Understand Staphylococcus Aureus Behavior. 15. Advancements in Staphylococcus aureus Vaccine Development: Recent Insights. 16. Addressing Challenges and Exploring Future Prospects in Drug Development Against Staphylococcus Aureus.
About the Author :
Anjaneyulu Musini is an Assistant Professor at the Centre for Biotechnology, University College of Engineering, Science and Technology, Jawaharlal Nehru Technological University (JNTU), Hyderabad, India. He earned his Ph.D. in Biotechnology in 2016 from the Institute of Science and Technology, JNTUH, and has over 15 years of academic and research experience in the areas of Biotechnology, Microbiology, and Natural Product Pharmacology. Dr. Musini completed his M.Tech. research at the Department of Biochemistry, Indian Institute of Science (IISc), Bangalore, where he developed a strong foundation in anticancer and antimicrobial research. His current research interests include the discovery and characterization of bioactive compounds from medicinal plants, drug-resistant pathogens, fermentation-based production of biomolecules such as L-Arginine, and natural product pharmacology. He has also contributed to interdisciplinary research in the fields of bioplastics, biofilms, nanoparticles, and quorum sensing inhibitors. He has successfully completed a TEQIP-III-funded R&D project investigating the antibacterial properties of Salacia oblonga against drug-resistant Staphylococcus aureus. His doctoral work focused on the extensive phytochemical and biological characterization of Salacia oblonga, resulting in several high-impact publications. Dr. Musini has published over 16 peer-reviewed journal articles, 10 book chapters, and one book. He holds one published patent and has filed a design patent. His research has been presented at numerous national and international conferences. In addition to his research, Dr. Musini actively contributes to academic development through curriculum design, participation in the Internal Quality Assurance Cell (IQAC), and involvement in NBA accreditation processes at JNTUH. He has guided M.Sc. and M.Tech. students in Biotechnology and Microbiology and is skilled in diverse technical areas ranging from molecular biology to fermentation technology. His qualifications and recognitions include the GATE (2007), DST-TIFAC Senior Research Fellowship (2010), Canadian Commonwealth Fellowship (2012), and UGC-SET qualification (2018). He has also completed several NPTEL-FDP certifications. With nine years of post-doctoral teaching and research experience, Dr. Musini was recently appointed as an editorial board member of Scientific Reports (Springer Nature).
Narasaiah Kolliputi is a distinguished Associate Professor at the University of South Florida (USF), Morsani College of Medicine, with interdisciplinary appointments in the Departments of Pathology & Cell Biology, Pharmaceutical Sciences, Internal Medicine, Pediatrics, and Molecular Medicine. He joined USF in 2010 as an Assistant Professor in the Division of Allergy and Immunology and was tenured and promoted to Associate Professor in 2013. Dr. Kolliputi completed his postdoctoral training in Physiology at Oklahoma State University (2004–2006), followed by advanced research in Pulmonary and Critical Care Medicine at Massachusetts General Hospital and Harvard Medical School (2006–2008), where he subsequently served as a Research Scientist (2008–2009) before joining USF. A recognized expert in lung injury, inflammasome biology, oxidative stress, and redox signaling, Dr. Kolliputi has built a translational research program that bridges basic molecular mechanisms with clinical implications in acute lung injury, pulmonary fibrosis, asthma, and inflammatory cell death (PANoptosis). His research has been continuously supported by the NIH, including R01, R21, and R56 awards totaling nearly $2.91 million (2013–2020), an AHA National Scientist Development Grant ($308K), and multiple USF institutional awards (Internal, PEG, G, and GME). In total, his PI-level portfolio exceeds $4.49M, and his cumulative research portfolio, including Co-I and trainee-linked funding, exceeds $5.73M. Dr. Kolliputi’s research productivity is reflected in over 100 peer-reviewed publications, including 27 papers from the past five years in high-impact journals such as Scientific Reports, Frontiers in Pharmacology, FASEB Journal, Aging Cell, and The American Journal of Physiology. His laboratory has been awarded two U.S. patents, and he was elected to the USF Chapter of the National Academy of Inventors (NAI), with a dedicated brick at the Inventors Commons in the USF Research Park. A committed mentor and educator, Dr. Kolliputi has trained over 100 undergraduate, graduate, and medical trainees, many of whom have achieved national recognition through AHA postdoctoral and predoctoral fellowships, GME Research Awards, an AΩA Student Research Fellowship, and USF Health Research Day honors. In recognition of his contributions to science and education, he has received numerous institutional awards, including the USF Outstanding Research Achievement Award (2017), the Internal Medicine Outstanding Research Award (2017), and the Theodore and Venette Askounes-Ashford Distinguished Scholar Award (2018). He also received the Young Investigator Award from the Society for Experimental Biology and Medicine (SEBM). Dr. Kolliputi serves as Chairman of NIH Study Sections and Special Emphasis Panels (NHLBI) and as Associate Editor for Frontiers in Pharmacology, Frontiers in Physiology, and Frontiers in Genetics, while also serving as a reviewer for the NIH, DoD, AHA, and leading scientific journals.Through his innovative research, mentorship, and leadership, Dr. Kolliputi continues to advance USF’s translational mission, expanding the national and international visibility of the Division of Allergy and Immunology.
Vinod Kumar Yata is currently serving as an Associate professor at School of Allied and Healthcare Sciences, Malla Reddy University, Hyderabad, Telangana, India. Previously, he served as an Assistant professor at Department of Molecular Biology, Central University of Andhrapradesh, India. Prior to this role, he worked as a Research Scientist at the Center of Excellence for Aging and Brain Repair at the University of South Florida (USF) in Tampa, Florida, USA. He also worked as a Research Associate at the National Dairy Research Institute in Karnal, India. Previously, he also worked as an assistant professor at the Department of Biotechnology, Dr. B R Ambedkar National Institute of Technology Jalandhar, Punjab, India. He received his Ph.D. in Biotechnology from Indian Institute of Technology Guwahati. He specializes in interdisciplinary research which includes Animal Biotechnology, Microbiome in aging, Cancer biology, Nanotechnology, Microfluidics, and Bioinformatics. He has developed a microfluidic device for the separation of live and motile spermatozoa from cattle semen samples. He has published several research articles in peer reviewed international journals and presented papers in several international conferences. He published eight books as an editor and two books as an author.
